Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Employment agrmnt
Quarterly results
Auditor change
Consulting agrmnt

PIERIS PHARMACEUTICALS, INC. (PIRS) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/18/2023 8-K Quarterly results
07/13/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/08/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Presentation, dated June 2023"
05/19/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
05/10/2023 8-K Quarterly results
Docs: "Three Months Ended March 31, 2023 2022 Revenues $ 1,936 $ 10,988 Operating expenses Research and development 13,424 14,066 General and administrative 4,023 4,379 Total operating expenses 17,447 18,445 Loss from operations Interest income 357 Grant income 2,028 2,130 Other income , net (57 229 Net loss",
"Investor Presentation, dated May 2023"
03/29/2023 8-K Quarterly results
01/10/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Press Release"
11/04/2022 8-K Quarterly results
11/02/2022 8-K Quarterly results
11/01/2022 8-K Quarterly results
09/13/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "PIERIS PHARMACEUTICALS SUPERIOR MEDICINES THROUGH EFFICIENT BIOLOGY CORPORATE PRESENTATION"
08/04/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/04/2022 8-K Quarterly results
Docs: "PIERIS PHARMACEUTICALS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON",
"PIERIS PHARMACEUTICALS SUPERIOR MEDICINES THROUGH EFFICIENT BIOLOGY CORPORATE PRESENTATION"
06/24/2022 8-K Quarterly results
06/08/2022 8-K Quarterly results
05/25/2022 8-K Quarterly results
05/11/2022 8-K/A Quarterly results
05/11/2022 8-K Quarterly results
03/01/2022 8-K Quarterly results
01/24/2022 8-K Investor presentation
Docs: "PIERIS PHARMACEUTICALS SUPERIOR MEDICINES THROUGH EFFICIENT BIOLOGY CORPORATE PRESENTATION"
01/14/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "PIERIS PHARMACEUTICALS ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 2 GASTRIC CANCER TRIAL OF 4-1BB/HER2 BISPECIFIC CINREBAFUSP ALFA"
01/14/2022 8-K/A Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
01/03/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "PIERIS PHARMACEUTICALS ANNOUNCES SUCCESSFUL COMPLETION OF SAFETY MILESTONE AND INITIATION OF EFFICACY PORTION OF PHASE 2A TRIAL OF PRS-060/AZD1402"
11/18/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "PIERIS PHARMACEUTICALS SUPERIOR MEDICINES THROUGH EFFICIENT BIOLOGY CORPORATE PRESENTATION"
11/02/2021 8-K Quarterly results
Docs: "PRESS RELEASE PIERIS PHARMACEUTICALS REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON TUESDAY, NOVEMBER 2, 2021 AT 8:00 AM EDT"
10/06/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Executive Director, Investor Relations"
08/30/2021 8-K Quarterly results
08/24/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "0 1 2 3 4",
"PRESS RELEASE PIERIS PHARMACEUTICALS ANNOUNCES PRS-220 PRESENTATION AT ERS HIGHLIGHTING PRECLINICAL DATA FOR CTGF INHIBITOR BOSTON, MA,"
08/04/2021 8-K Quarterly results
Docs: "PRESS RELEASE PIERIS PHARMACEUTICALS REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON WEDNESDAY, AUGUST 4, 2021 AT 8:00 AM EDT",
"PIERIS PHARMACEUTICALS SUPERIOR MEDICINES THROUGH EFFICIENT BIOLOGY CORPORATE PRESENTATION"
06/29/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Pieris Pharmaceuticals, Inc. 2020 Employee, Director and Consultant Equity Incentive Plan, as Amended"
06/25/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "PRESS RELEASE PIERIS PHARMACEUTICALS ANNOUNCES INHALED CTGF INHIBITOR PRS-220 FOR IDIOPATHIC PULMONARY FIBROSIS AND 17 MILLION DOLLAR GRANT FROM BAVARIAN GOVERNMENT TO ACCELERATE PROGRAM DEVELOPMENT FOR POST-COVID-19 PULMONARY FIBROSIS",
"PIERIS PHARMACEUTICALS SUPERIOR MEDICINES THROUGH EFFICIENT BIOLOGY CORPORATE PRESENTATION"
05/25/2021 8-K Quarterly results
05/25/2021 8-K Quarterly results
05/21/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy